12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Company News  |  Deals

Aeterna Zentaris, Ergomed deal

Aeterna partnered with CRO Ergomed to co-develop Zoptarelin doxorubicin acetate ( AEZS-108) to treat endometrial cancer. Ergomed will be responsible for 30% of the costs for a Phase III trial, which is slated to...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >